Total trials
3,620
Active
155
Phase 3
890
Total enrollment
6,397,901
Pipeline matrix
Showing 40 of 202 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Dostarlimab | — | — | 28 | ||||
| Depemokimab | — | — | — | 13 | |||
| Paclitaxel | — | 22 | |||||
| Belimumab | — | 19 | |||||
| Carboplatin | — | — | 12 | ||||
| Niraparib | — | — | 6 | ||||
| Mepolizumab | — | — | 28 | ||||
| rMenB+OMV NZ | — | — | — | — | 2 | ||
| Fluticasone furoate/umeclidinium bromide/vilanterol trifenatate | — | — | — | — | — | 1 | |
| Inhaled corticosteroids/long-acting beta-2 agonists | — | — | — | — | — | 1 | |
| Recombinant zoster vaccine | — | — | — | — | — | 1 | |
| Belantamab mafodotin | — | — | — | 29 | |||
| Dexamethasone | — | — | — | 21 | |||
| Bortezomib | — | — | — | 12 | |||
| Pembrolizumab | — | — | — | 19 | |||
| Bevacizumab | — | — | — | 7 | |||
| Efimosfermin alfa | — | — | — | — | 6 | ||
| Pomalidomide | — | — | — | 6 | |||
| Mocertatug rezetecan | — | — | — | — | 5 | ||
| Belrestotug | — | — | — | 5 | |||
| Hepatitis A vaccine | — | — | — | — | 5 | ||
| Lenalidomide | — | — | — | 5 | |||
| PCV (pneumococcal conjugate vaccine) 13 | — | — | — | — | — | 4 | |
| PCV 20 | — | — | — | — | — | 4 | |
| Vaxneuvance | — | — | — | — | — | 4 | |
| Daratumumab | — | — | — | — | — | 4 | |
| Ris-Rez | — | — | — | 4 | |||
| MMR vaccine | — | — | — | — | 4 | ||
| Cobolimab | — | — | — | 4 | |||
| Marketed varicella vaccine | — | — | — | — | — | 3 | |
| Momelotinib | — | — | — | 4 | |||
| Gemcitabine | — | — | — | 7 | |||
| RSVPreF3 OA vaccine | — | — | — | — | — | 4 | |
| CAPEOX | — | — | — | 3 | |||
| Investigational varicella vaccine | — | — | — | — | — | 2 | |
| Pegylated liposomal doxorubicin | — | — | — | — | — | 2 | |
| Velzatinib | — | — | — | — | 2 | ||
| topotecan | — | — | 19 | ||||
| FF/UMEC/VI | — | — | — | — | 10 | ||
| Docetaxel | — | — | — | 16 |
162 more active programs hidden
Next readouts
- 2022-06-06
- 2022-09-12
- 2023-01-16
- 2023-10-02
- 2024-01-29
- 2024-04-03
- 2024-04-03
- 2024-04-04
- 2024-05-27
- 2024-06-28
Top conditions
- Pulmonary Disease, Chronic Obstructive251
- Asthma244
- Influenza147
- Hepatitis B125
- Diabetes Mellitus, Type 2110
- Diphtheria87
- Tetanus86
- Cancer68
Frequently asked questions about GlaxoSmithKline
- How many clinical trials does GlaxoSmithKline have on ClinicalTrials.gov?
- GlaxoSmithKline is listed as the lead sponsor on 3,620 clinical trials in ClinicalTrials.gov, 155 of which are currently active (recruiting, enrolling, or ongoing).
- How many of GlaxoSmithKline's trials are in Phase 3?
- 890 of GlaxoSmithKline's trials are in Phase 3, spread across 202 active drug programs.
- What therapeutic areas does GlaxoSmithKline focus on?
- GlaxoSmithKline's most-studied conditions on ClinicalTrials.gov are Pulmonary Disease, Chronic Obstructive, Asthma, Influenza, Hepatitis B, Diabetes Mellitus, Type 2.
- When are GlaxoSmithKline's next clinical trial readouts?
- GlaxoSmithKline has 10 upcoming primary-completion readouts tracked here; the soonest is “Immunogenicity, Safety, Reactogenicity and Persistence of an Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above”, expected around 2022-06-06.